Combined anti-PD-1/CTLA-4 blockade leads to a high rate of durable responses in dMMR/MSI-H non-CRC cancers comparing favourably to published trials using anti-PD-1/PD-L1 monotherapy. Here, CTLA4 is linked to colorectal carcinoma.